Fink Kyle D, Rossignol Julien, Lu Ming, Lévêque Xavier, Hulse Travis D, Crane Andrew T, Nerriere-Daguin Veronique, Wyse Robert D, Starski Phillip A, Schloop Matthew T, Dues Dylan J, Witte Steve J, Song Cheng, Vallier Ludovic, Nguyen Tuan H, Naveilhan Philippe, Anegon Ignacio, Lescaudron Laurent, Dunbar Gary L
Program in Neuroscience, Field Neurosciences Laboratory for Restorative Neurology Brain Research and Integrative Neuroscience Center, Central Michigan University, Mount Pleasant, MI, USA.
Cell Transplant. 2014;23(11):1407-23. doi: 10.3727/096368913X670958. Epub 2013 Jul 22.
Induced pluripotent stem cells (iPSCs) offer certain advantages over embryonic stem cells in cell replacement therapy for a variety of neurological disorders. However, reliable procedures, whereby transplanted iPSCs can survive and differentiate into functional neurons, without forming tumors, have yet to be devised. Currently, retroviral or lentiviral reprogramming methods are often used to reprogram somatic cells. Although the use of these viruses has proven to be effective, formation of tumors often results following in vivo transplantation, possibly due to the integration of the reprogramming genes. The goal of the current study was to develop a new approach, using an adenovirus for reprogramming cells, characterize the iPSCs in vitro, and test their safety, survivability, and ability to differentiate into region-appropriate neurons following transplantation into the rat brain. To this end, iPSCs were derived from bone marrow-derived mesenchymal stem cells and tail-tip fibroblasts using a single cassette lentivirus or a combination of adenoviruses. The reprogramming efficiency and levels of pluripotency were compared using immunocytochemistry, flow cytometry, and real-time polymerase chain reaction. Our data indicate that adenovirus-generated iPSCs from tail-tip fibroblasts are as efficient as the method we used for lentiviral reprogramming. All generated iPSCs were also capable of differentiating into neuronal-like cells in vitro. To test the in vivo survivability and the ability to differentiate into region-specific neurons in the absence of tumor formation, 400,000 of the iPSCs derived from tail-tip fibroblasts that were transfected with the adenovirus pair were transplanted into the striatum of adult, immune-competent rats. We observed that these iPSCs produced region-specific neuronal phenotypes, in the absence of tumor formation, at 90 days posttransplantation. These results suggest that adenovirus-generated iPSCs may provide a safe and viable means for neuronal replacement therapies.
在针对多种神经疾病的细胞替代疗法中,诱导多能干细胞(iPSC)相较于胚胎干细胞具有某些优势。然而,尚未设计出可靠的程序,使移植的iPSC能够存活并分化为功能性神经元,同时不形成肿瘤。目前,逆转录病毒或慢病毒重编程方法常被用于对体细胞进行重编程。尽管已证明使用这些病毒是有效的,但体内移植后往往会形成肿瘤,这可能是由于重编程基因的整合所致。本研究的目的是开发一种新方法,使用腺病毒对细胞进行重编程,在体外对iPSC进行表征,并测试其安全性、生存能力以及移植到大鼠脑内后分化为区域合适神经元的能力。为此,使用单一盒式慢病毒或腺病毒组合,从骨髓来源的间充质干细胞和尾尖成纤维细胞中获得iPSC。使用免疫细胞化学、流式细胞术和实时聚合酶链反应比较重编程效率和多能性水平。我们的数据表明,来自尾尖成纤维细胞的腺病毒生成的iPSC与我们用于慢病毒重编程的方法一样有效。所有生成的iPSC在体外也能够分化为神经元样细胞。为了测试在无肿瘤形成情况下的体内生存能力以及分化为区域特异性神经元的能力,将40万个用腺病毒对转染的来自尾尖成纤维细胞的iPSC移植到成年、具有免疫能力的大鼠纹状体中。我们观察到,在移植后90天,这些iPSC在无肿瘤形成的情况下产生了区域特异性神经元表型。这些结果表明,腺病毒生成的iPSC可能为神经元替代疗法提供一种安全可行的方法。